作者:Sang-Phyo Hong、Kevin G. Liu、Gil Ma、Michael Sabio、Michelle A. Uberti、Maria D. Bacolod、John Peterson、Zack Z. Zou、Albert J. Robichaud、Darío Doller
DOI:10.1021/jm200290z
日期:2011.7.28
There is an increasing amount of evidence to support that activation of the metabotropicglutamatereceptor4 (mGlu4 receptor), either with an orthosteric agonist or a positiveallostericmodulator (PAM), provides impactful interventions in diseases such as Parkinson’s disease, anxiety, and pain. mGlu4 PAMs may have several advantages over mGlu4 agonists for a number of reasons. As part of our efforts